All In Biotech

Free tool

FAERS Monitor: Synjardy

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 206111 or its brand name (Synjardy, Empagliflozin, Metformin Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

2,950

Serious

1,857

63% of reports

Hospitalization

986

Death reported

112

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nausea213
  • blood glucose increased192
  • vomiting189
  • diarrhoea158
  • diabetic ketoacidosis156
  • weight decreased144
  • fatigue131
  • ketoacidosis124
  • drug ineffective117
  • dizziness109
  • off label use101
  • decreased appetite88
  • asthenia87
  • pain87
  • urinary tract infection85

Reports by year received

View as table
YearReports
20131
20154
201658
2017116
2018185
2019291
2020300
2021300
2022358
2023413
2024350
2025289
2026285

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,209 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
ketoacidosisSignal124120.1101.014,293
diabetic ketoacidosisSignal15646.640.06,879
blood glucose increasedSignal1927.36.31,041
weight decreasedSignal1443.73.1282
urinary tract infectionSignal853.62.9155
vomitingSignal1892.92.5233
decreased appetiteSignal882.72.294
nausea2131.91.796
diarrhoea1581.71.551
asthenia871.61.322
dizziness1091.61.322
fatigue1311.21.04
pain871.00.80
off label use1010.80.74
drug ineffective1170.60.526

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.